Skip to content

The Designer D-dimer Deep Vein Thrombosis Diagnosis (4D) Study

D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02038530
Acronym
4D
Enrollment
1513
Registered
2014-01-16
Start date
2014-02-28
Completion date
2020-10-15
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected Deep Vein Thrombosis

Keywords

Deep Vein Thrombosis

Brief summary

This is a cohort study that will assess a new diagnostic management strategy for suspected Deep Vein Thrombosis in outpatients.The new diagnostic strategy is designed to reduce the use of ultrasound testing on the day of presentation, and reduce repeat ultrasound testing a week after an initial normal test.

Detailed description

This is a prospective, multicentre, cohort study that will assess a new diagnostic management strategy for suspected Deep Vein Thrombosis in outpatients. The new diagnostic strategy is designed to reduce the use of ultrasound testing on the day of presentation, and reduce repeat ultrasound testing a week after an initial normal test. Less ultrasound testing will be performed because: i) more patients will have deep vein thrombosis excluded by combinations of Clinical Pretest Probability and D-dimer results on the day of presentation; and, ii) in those who still need an ultrasound, a repeat ultrasound a week after a normal result will only be performed if the D-dimer result is markedly abnormal at initial presentation. The safety of this management strategy will be established by demonstrating a very low rate of proximal Deep Vein Thrombosis or Pulmonary Embolism during 90 days follow-up in patients who had anticoagulant therapy withheld in response to negative diagnostic testing. Diagnostic test utilization will be assessed. All clinical outcomes will be adjudicated by a central independent adjudication committee that will be blind to initial D-dimer measurements and patient management.

Interventions

None listed

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
McMaster University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1\) Consecutive outpatients (i.e. non-hospitalized patients) with clinically suspected Deep Vein Thrombosis.

Exclusion criteria

1. Age less than 18 years. 2. Treated with full-dose anticoagulation for ≥ 24 hours before D-dimer was measured. 3. D-dimer level known before Clinical Pretest Probability documented. 4. Ultrasound of the leg performed before Clinical Pretest Probability was documented 5. Ultrasound was or will be performed in a patient with low Clinical Pretest Probability and a d-dimer \<1000(or equivalent), or with Moderate Clinical Pretest Probability and a D-dimer \<500 (or equivalent) (e.g. suspected bleeding). 6. Ongoing need for anticoagulant therapy. 7. Suspected Pulmonary Embolism. 8. Superficial venous thrombosis that requires, or may require, anticoagulant therapy. 9. Life expectancy less than 3 months. 10. Previously confirmed episode of Deep Vein Thrombosis. 11. Geographic inaccessibility which precludes follow-up. 12. Known pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Confirmed symptomatic proximal Deep Vein Thrombosiswithin 90 daysThe primary outcome is confirmed symptomatic proximal Deep Vein Thrombosis (including involvement of the calf vein trifurcation but not isolated more distal Deep Vein Thrombosis; or pulmonary embolism (not including isolated sub-segmental abnormalities on Computed Tomography Pulmonary Angiogram; within 90 days (± 7 days for follow-up assessment) that is not diagnosed by scheduled diagnostic testing (includes events that occur between initial and scheduled follow-up proximal ultrasound examinations).

Secondary

MeasureTime frameDescription
Clinical Pretest Probability/ D-dimer/ Compression Ultrasound subgroupswithin 90 daysThe primary outcome in the following subgroups: * Low Clinical Pretest Probability and D-dimer \<1000 ug/L * Moderate Clinical Pretest Probability and D-dimer \<500 ug/L * Moderate Clinical Pretest Probability and D-dimer 500 -999 ug/L * High Clinical Pretest Probability and D-dimer \<500 ug/L * Low Clinical Pretest Probability and D-dimer 1000-2999 ug/L and negative initial ultrasound * Moderate Clinical Pretest Probability and D-dimer 1000-2999 ug/L and negative initial ultrasound * High Clinical Pretest Probability and D-dimer 500-1499 ug/L and negative initial ultrasound
Deathwithin 90 daysDeath within 90 days (± 7 days for follow-up assessment).

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026